Severe Psoriasis-Pipeline Insights, 2016

Description: "Severe Psoriasis-Pipeline Insights, 2016" provides in depth insight on the pipeline drugs and their development activities around the Severe Psoriasis. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. The Report covers the product clinical trials information and other development activities including technology, licensing, collaboration, acquisitions, funding, patent and USFDA & EMA designations details. The Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Severe Psoriasis. The report also assesses the Severe Psoriasis therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Scope

- The report provides competitive pipeline landscape of Severe Psoriasis
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Severe Psoriasis pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report review the key players involved in the therapeutics development for Severe Psoriasis and also provides company profiling
- The report also gives the information on dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from pre registration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy

- Complete Pipeline intelligence and complete understanding over therapeutic development for Severe Psoriasis
- Identify the relationship between the drugs and its use for target finding, drug repurposing, and precision medicine.
- Devise corrective measure for pipeline projects by understanding Severe Psoriasis pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimizing the portfolio and keep in touch with the rapid changing pharmaceutical market, and make the best decision for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insight to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a clear picture of the competitive landscape for evidence based decisions

Contents:

- Severe Psoriasis Overview
- Severe Psoriasis Pipeline Therapeutics
- Severe Psoriasis Therapeutics under Development by Companies
- Severe Psoriasis Filed and Phase III Products
- Comparative Analysis
- Severe Psoriasis Phase II Products
- Comparative Analysis
- Severe Psoriasis Phase I and IND Filed Products
- Comparative Analysis
- Severe Psoriasis Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
  - Severe Psoriasis – Therapeutics Assessment
  - Assessment by Monotherapy Products
  - Assessment by Combination Products
  - Assessment by Route of Administration
  - Assessment by Molecule Type
  - Severe Psoriasis – Discontinued Products
  - Severe Psoriasis – Dormant Products
- Companies Involved in Therapeutics Development for Severe Psoriasis
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables
- Number of Products under Development for Severe Psoriasis, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
  - Severe Psoriasis Assessment by Monotherapy Products
  - Severe Psoriasis Assessment by Combination Products
  - Severe Psoriasis Assessment by Route of Administration
  - Severe Psoriasis Assessment by Stage and Route of Administration
  - Severe Psoriasis Assessment by Molecule Type
  - Severe Psoriasis Assessment by Stage and Molecule Type
  - Severe Psoriasis Therapeutics – Discontinued Products
  - Severe Psoriasis Therapeutics – Dormant Products
- Products under Development by Companies, 2016

List of Figures
- Number of Products under Development for Severe Psoriasis, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Severe Psoriasis Assessment by Monotherapy Products
- Severe Psoriasis Assessment by Combination Products
- Severe Psoriasis Assessment by Route of Administration
- Severe Psoriasis Assessment by Stage and Route of Administration
- Severe Psoriasis Assessment by Molecule Type
- Severe Psoriasis Assessment by Stage and Molecule Type

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Severe Psoriasis-Pipeline Insights, 2016
Web Address: http://www.researchandmarkets.com/reports/3533293/
Office Code: SCD2UVSN

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 1250</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 4000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  
Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐  
First Name: ___________________________  Last Name: ___________________________

Email Address: * ___________________________

Job Title: ___________________________

Organisation: ___________________________

Address: ___________________________

City: ___________________________

Postal / Zip Code: ___________________________

Country: ___________________________

Phone Number: ___________________________

Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ______________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp